3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
13
Phase 1/2
7
Phase 1
7
Phase 3
2
Phase EARLY_PHASE1
1
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Lymphoma
6
Leukemia
6
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, Non-Hodgkin
4
Recurrence
3
Sezary Syndrome
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Myelodysplastic Syndromes
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Follicular
2
Leukemia, T-Cell
2
Leukemia, Myeloid, Acute
2
Leukemia, Biphenotypic, Acute
2
Congenital Abnormalities
2
Waldenstrom Macroglobulinemia
1
Thrombocythemia, Essential
1
Testicular Neoplasms
1
Testicular Germ Cell Tumor
1
Teratoma
1
Small Cell Lung Carcinoma
1
Seminoma
1
Sarcoma, Ewing
1
Retinoblastoma
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Neuroblastoma
1
Neoplasms
1
Myeloproliferative Disorders
1
Interventions
Rituximab
2
loncastuximab tesirine
1
etoposide phosphate
1
blinatumomab
1
Tubercidin
1
Immunotherapy, Adoptive
1
Ifosfamide
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Lymphoma, B-Cell
×
Etoposide
×
Clear all
NCT05991388
2026-02-20
Glo-BNHL
University of Birmingham
Phase 2/3
Recruiting
210 enrolled